# EDGAR Filing Document

**Accession Number:** 0001728970
**File Stem:** 0001213900-26-067505
**Filing Date:** 2026-6
**Character Count:** 18387
**Document Hash:** 213e57c95343fe1b477a66e8a2420da9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-067505.hdr.sgml**: 20260610

**ACCESSION NUMBER**: 0001213900-26-067505

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260520

**FILED AS OF DATE**: 20260610

**DATE AS OF CHANGE**: 20260610

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Vivo Opportunity Cayman Fund, L.P.
- **CENTRAL INDEX KEY:** 0001875722

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39685
- **FILM NUMBER:** 261081245

**BUSINESS ADDRESS:**
- **STREET 1:** 192 LYTTON AVENUE
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94301
- **BUSINESS PHONE:** (650) 688-0818

**MAIL ADDRESS:**
- **STREET 1:** 192 LYTTON AVENUE
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94301

**FORMER NAME:**
- **FORMER CONFORMED NAME:** Vivo Asia Opportunity Fund, L.P.
- **DATE OF NAME CHANGE:** 20210729
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Vivo Opportunity, LLC
- **CENTRAL INDEX KEY:** 0001728970

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39685
- **FILM NUMBER:** 261081248

**BUSINESS ADDRESS:**
- **STREET 1:** 192 LYTTON AVENUE
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94301
- **BUSINESS PHONE:** 6506880818

**MAIL ADDRESS:**
- **STREET 1:** 192 LYTTON AVENUE
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94301
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Vivo Opportunity Fund Holdings, L.P.
- **CENTRAL INDEX KEY:** 0001930214

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39685
- **FILM NUMBER:** 261081247

**BUSINESS ADDRESS:**
- **STREET 1:** 192 LYTTON AVENUE
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94301
- **BUSINESS PHONE:** 6506880818

**MAIL ADDRESS:**
- **STREET 1:** 192 LYTTON AVENUE
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94301
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Vivo Opportunity Cayman, LLC
- **CENTRAL INDEX KEY:** 0001930113

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39685
- **FILM NUMBER:** 261081246

**BUSINESS ADDRESS:**
- **STREET 1:** 192 LYTTON AVENUE
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94301
- **BUSINESS PHONE:** 6506880818

**MAIL ADDRESS:**
- **STREET 1:** 192 LYTTON AVENUE
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94301

**FORMER NAME:**
- **FORMER CONFORMED NAME:** Vivo Asia Opportunity, LLC
- **DATE OF NAME CHANGE:** 20220519
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** InMed Pharmaceuticals Inc.
- **CENTRAL INDEX KEY:** 0001728328
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0630

**BUSINESS ADDRESS:**
- **STREET 1:** 1445-885 WEST GEORGIA ST.
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6C 3E8
- **BUSINESS PHONE:** (604) 669-7207

**MAIL ADDRESS:**
- **STREET 1:** 1445-885 WEST GEORGIA ST.
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6C 3E8

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Vivo Opportunity, LLC<br><sub>(Last) (First) (Middle)</sub><br>192 LYTTON AVENUE<br><sub>(Street)</sub><br>PALO ALTO,, CA 94301<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-05-20 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>InMed Pharmaceuticals Inc. [ INM ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Vivo Opportunity Fund Holdings, L.P.<br><sub>(Last) (First) (Middle)</sub><br>192 LYTTON AVENUE<br><sub>(Street)</sub><br>PALO ALTO,, CA 94301<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-05-20 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>InMed Pharmaceuticals Inc. [ INM ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Vivo Opportunity Cayman, LLC<br><sub>(Last) (First) (Middle)</sub><br>192 LYTTON AVENUE<br><sub>(Street)</sub><br>PALO ALTO,, CA 94301<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-05-20 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>InMed Pharmaceuticals Inc. [ INM ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Vivo Opportunity Cayman Fund, L.P.<br><sub>(Last) (First) (Middle)</sub><br>192 LYTTON AVENUE<br><sub>(Street)</sub><br>PALO ALTO,, CA 94301<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-05-20 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>InMed Pharmaceuticals Inc. [ INM ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Shares | 2026-05-20 |  | P |  | 51056 | A | 1.56<sup>(3)</sup> | 543129 | I | By Vivo Opportunity Fund Holdings, L.P.<sup>(1)</sup> |
| Common Shares | 2026-05-20 |  | P |  | 5154 | A | 1.56<sup>(3)</sup> | 54833 | I | By Vivo Opportunity Cayman Fund, L.P.<sup>(2)</sup> |
| Common Shares | 2026-05-21 |  | P |  | 30882 | A | 1.69<sup>(4)</sup> | 574011 | I | By Vivo Opportunity Fund Holdings, L.P.<sup>(1)</sup> |
| Common Shares | 2026-05-21 |  | P |  | 3118 | A | 1.69<sup>(4)</sup> | 57951 | I | By Vivo Opportunity Cayman Fund, L.P.<sup>(2)</sup> |
| Common Shares | 2026-05-29 |  | P |  | 16164 | A | 1.57<sup>(5)</sup> | 590175 | I | By Vivo Opportunity Fund Holdings, L.P.<sup>(1)</sup> |
| Common Shares | 2026-05-29 |  | P |  | 1632 | A | 1.57<sup>(5)</sup> | 59583 | I | By Vivo Opportunity Cayman Fund, L.P.<sup>(2)</sup> |
| Common Shares | 2026-06-01 |  | P |  | 14838 | A | 1.55<sup>(6)</sup> | 605013 | I | By Vivo Opportunity Fund Holdings, L.P.<sup>(1)</sup> |
| Common Shares | 2026-06-01 |  | P |  | 1498 | A | 1.55<sup>(6)</sup> | 61081 | I | By Vivo Opportunity Cayman Fund, L.P.<sup>(2)</sup> |
| Common Shares | 2026-06-02 |  | P |  | 20753 | A | 1.52<sup>(7)</sup> | 625766 | I | By Vivo Opportunity Fund Holdings, L.P.<sup>(1)</sup> |
| Common Shares | 2026-06-02 |  | P |  | 2095 | A | 1.52<sup>(7)</sup> | 63176 | I | By Vivo Opportunity Cayman Fund, L.P.<sup>(2)</sup> |
| Common Shares | 2026-06-03 |  | P |  | 7069 | A | 1.55<sup>(8)</sup> | 632835 | I | By Vivo Opportunity Fund Holdings, L.P.<sup>(1)</sup> |
| Common Shares | 2026-06-03 |  | P |  | 714 | A | 1.55<sup>(8)</sup> | 63890 | I | By Vivo Opportunity Cayman Fund, L.P.<sup>(2)</sup> |
| Common Shares | 2026-06-04 |  | P |  | 6125 | A | 1.57<sup>(9)</sup> | 638960 | I | By Vivo Opportunity Fund Holdings, L.P.<sup>(1)</sup> |
| Common Shares | 2026-06-04 |  | P |  | 618 | A | 1.57<sup>(9)</sup> | 64508 | I | By Vivo Opportunity Cayman Fund, L.P.<sup>(2)</sup> |
| Common Shares | 2026-06-05 |  | P |  | 49966 | A | 1.57<sup>(10)</sup> | 688926 | I | By Vivo Opportunity Fund Holdings, L.P.<sup>(1)</sup> |
| Common Shares | 2026-06-05 |  | P |  | 5045 | A | 1.57<sup>(10)</sup> | 69553 | I | By Vivo Opportunity Cayman Fund, L.P.<sup>(2)</sup> |
| Common Shares | 2026-06-08 |  | P |  | 29518 | A | 1.52<sup>(11)</sup> | 718444 | I | By Vivo Opportunity Fund Holdings, L.P.<sup>(1)</sup> |
| Common Shares | 2026-06-08 |  | P |  | 2982 | A | 1.52<sup>(11)</sup> | 72535 | I | By Vivo Opportunity Cayman Fund, L.P.<sup>(2)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

---

### Footnotes:

(1) Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

(2) Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

(3) The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.42 to $1.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4.

(4) The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.53 to $1.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4.

(5) The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.55 to $1.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (5) to this Form 4.

(6) The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.49 to $1.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (6) to this Form 4.

(7) The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.49 to $1.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (7) to this Form 4.

(8) The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.50 to $1.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (8) to this Form 4.

(9) The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.55 to $1.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (9) to this Form 4.

(10) The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.53 to $1.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (10) to this Form 4.

(11) The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.48 to $1.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (11) to this Form 4.

**Signature:** VIVO OPPORTUNITY, LLC, By: /s/ Kevin Dai  
**Date:** 2026-06-10

**Signature:** VIVO OPPORTUNITY FUND HOLDINGS, L.P., By: Vivo Opportunity, LLC, its general partner, By: /s/ Kevin Dai  
**Date:** 2026-06-10

**Signature:** VIVO OPPORTUNITY CAYMAN, LLC, By: /s/ Kevin Dai  
**Date:** 2026-06-10

**Signature:** VIVO OPPORTUNITY CAYMAN FUND, L.P., By: Vivo Opportunity Cayman, LLC, its general partner, By: /s/ Kevin Dai  
**Date:** 2026-06-10

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**